At AACR 2026, multiple early-phase studies reported clinical activity across targeted and antibody-drug conjugate approaches in difficult solid-tumor settings. In one readout, zoldonrasib—an investigational KRAS G12D inhibitor—reported objective responses with a manageable safety profile in previously treated NSCLC cohorts, with 52% confirmed objective response rate in an evaluable group. AACR presentations also included Phase I data for the CLDN6-targeting ADC QLS5132 in platinum-resistant ovarian cancer. In a single-arm dose-escalation trial, treatment-related adverse events were common but no grade-based red flags including ILD, ocular toxicity, or febrile neutropenia were reported; partial responses were observed after a short median follow-up. Separately, an engineering-first approach to solid-tumor cell therapy also surfaced: University of Pennsylvania investigators presented early Phase I data on SynKIR-110, a novel KIR-CAR design meant to mitigate exhaustion by using a multi-chain “on-off” architecture modeled on NK receptor biology. Across these readouts, AACR’s theme of de-risked target engagement and cell-therapy design optimization was reinforced by objective response and disease-stabilization signals, though all remain in early clinical stages.